Some Specific Highlights
From abroad, Dr. Maria Pantaleo, University of Bologna, Italy, presented to the Consortium in October, on three research SDH-related projects she is currently conducting. Though the results are not yet published, the team is optimistic about early results and they are engaging pathologists in discussion regarding their decision-making tree.
In the U.S., Dr. Jonathan Trent has opened a HIF2a trial at Sylvester Comprehensive Cancer Center, sharing details with the Consortium in order to
evaluate the possibility of SDH-deficient GIST patients as trial candidates.
Dr. Joshua Schiffman, Huntsman Cancer Institute, is focusing on a project for patients with PGL/PCC tumors (plus any SDH-driven tumors). With the Paraganglioma Preclinical Project, his team is working to test therapies and combinations of drugs to identify what can effectively stop these tumors from growing in mice. Read more: liferaftgroup.org/2018/12/new-in-sdh-deficient-research-the-paraganglioma-preclinical-project/.
Dr. Jason Sicklick, UCSD, is focusing on laboratory research with SDH-deficient GIST tissue. Drs.Schiffman and Sicklick are actively searching for tissue from recent surgeries and have appealed to GIST patients through the Consortium members and the resources of the LRG.
The Consortium will continue to meet monthly and future updates on the work of these experts and patient advocacy group will be posted.